IMMUNIC, INC.
IMUX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMUX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMUX
Immuunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic inflammatory and autoimmune diseases, with a lead program in Phase 3 for relapsing multiple sclerosis.
Key risk: Phase 3 trial failure risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$210.1M
Cash Runway
15.1 moLead Asset
imu-856 (Phase 3)
Next Catalyst
Phase3_Topline · Sep 1, 2033Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 2 catalysts for IMMUNIC, INC..
Immuunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic inflammatory and autoimmune diseases, with a lead program in Phase 3 for relapsing multiple sclerosis.
- Lead product candidate vidofludimus calcium (IMU-838) is in Phase 3 ENSURE trials for relapsing multiple sclerosis [sec_mda · as of 2026-08-11].
- Cash and equivalents of $155.1M as of 2026-06-30 [sec].
- Net loss of $34.1M for the period ended 2026-06-30 [sec].
- Shareholders' equity of -$6.7M as of 2026-06-30 [sec].
- Operating losses have been substantial, with $608.6M accumulated deficit as of December 31, 2025 [sec_mda · as of 2026-08-11].
What works
- Vidofludimus calcium has shown therapeutic activity in Phase 2 trials for relapsing-remitting and progressive multiple sclerosis, supporting advancement to Phase 3 [sec_mda · as of 2026-02-26].
- The company leverages a DHODH inhibition mechanism and has a pipeline including IMU-856 for bowel epithelium regeneration, potentially addressing multiple gastrointestinal indications [sec_mda · as of 2026-08-11].
- Operations are structured across Germany and Australia, with collaborations that may enable cost-effective execution of development programs [sec_mda · as of 2026-08-11].
What to weigh
- The company has a history of significant operating losses and expects to continue incurring increasing losses as it advances its pipeline [sec_mda · as of 2026-08-11].
- Shareholders' equity is negative (-$6.7M as of 2026-06-30), indicating accumulated deficits exceed assets [sec].
- Future funding needs may require additional equity or debt financing, with no assurance of availability on reasonable terms [sec_mda · as of 2026-08-11].
- The company is dependent on the success of its Phase 3 ENSURE trials; any negative outcome could materially impact its prospects [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Vidofludimus calcium is in Phase 3 for relapsing MS
“Executing and completing the ongoing twin Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS.”
SEC MD&A · August 11, 2026
Accumulated deficit of $608.6M as of December 31, 2025
“$608.6 million as of December 31, 2025”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2033-09-01 · Phase3_Topline — Phase 3 Topline: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Toler — Topline results from the Phase 3 ENSURE trial for vidofludimus calcium in relapsing MS are expected around this date.
- 2033-10-01 · Phase3_Topline — Phase 3 Topline: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Toler — Topline results from a second Phase 3 ENSURE trial for vidofludimus calcium in relapsing MS are expected around this date.
Risks & what to watch (4)›
Key risks
- Phase 3 trial failure risk — Negative results from the ongoing Phase 3 ENSURE trials could halt the lead program and impair the company's viability [sec_mda · as of 2026-08-11].
- Negative shareholders' equity — Shareholders' equity of -$6.7M as of 2026-06-30 indicates accumulated deficits exceed assets, raising going-concern risk [sec].
- Dependence on future financing — The company expects to need additional funds through debt, equity, or licensing, with no assurance of availability on reasonable terms [sec_mda · as of 2026-08-11].
- Operating loss trajectory — The company expects to continue incurring significant and increasing operating losses for the foreseeable future [sec_mda · as of 2026-08-11].
What to watch
- Topline data from the Phase 3 ENSURE trials for vidofludimus calcium in relapsing MS [sec_mda · as of 2026-08-11].
- Initiation of a Phase 3 program for vidofludimus calcium in progressive MS following Phase 2 CALLIPER results [sec_mda · as of 2026-08-11].
- Progress of the IMU-856 program targeting bowel epithelium regeneration [sec_mda · as of 2026-08-11].
- Changes in cash position and any new financing or partnership announcements [sec].
Sources: SEC filings · SEC MD&A · Generated August 18, 2026 · How we verify sources →
Run IMMUNIC, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IMMUNIC, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
15.1 months
D/E 0.25 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~2559d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$1.1M
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 952,966 | $1.1M |
| caldwell sutter capital, inc. | 3 | $3 |
| parallel advisors, llc | 2 | $2 |
Short Interest
as of Apr 20, 2026- % of float
- 7.7%
- Days to cover
- 2.9
- Shares short
- 8,954,740
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMUX short interestGovernance
Frequently asked questions
What is the AI investment thesis for IMMUNIC, INC.?
Immuunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic inflammatory and autoimmune diseases, with a lead program in Phase 3 for relapsing multiple sclerosis.
What is IMMUNIC, INC.'s lead drug candidate?
IMMUNIC, INC.'s most advanced tracked candidate is imu-856 (Phase 3) for celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease, and weight management.
What is IMMUNIC, INC.'s next catalyst?
IMMUNIC, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Toler" — expected September 1, 2033.
Who is the CEO of IMMUNIC, INC.?
Mr. Erik Lundgren is the chief executive officer of IMMUNIC, INC. (IMUX).
Where is IMMUNIC, INC. headquartered?
IMMUNIC, INC. (IMUX) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.